Telix Pharmaceuticals Limited was incorporated in Australia on January 3, 2017. The Company is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. Their mission is to become a global leader in radiopharmaceuticals, combining treatment and diagnosis for the benefit of patients, an innovative precision medicine concept often referred to as "therapeutic diagnostics. ". They have an extensive pipeline of therapeutic radiopharmaceutical candidates with a focus on urological oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. Their treatment approach aims to combine imaging and treatment to "observe and treat" cancer and rare diseases, better enabling patients to make treatment decisions and personalize treatment.